Morgan Stanley on bluebird bio (BLUE), 'the removal of the partial clinical hold is a positive'
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Underweight rating and $3.00 price target on bluebird bio (NASDAQ: BLUE).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
